Analysis of Mandatory Post‐Marketing Surveillance Studies Supports Revised Regulatory Requirements in Korea
Pharmacoepidemiology and Drug Safety · 2026-05 · 35 (5)
DOI: 10.1002/pds.70382 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmacoepidemiology and Drug Safety, online erschienen am 27.04.2026. Verfasst von Kevin Wolter und 7 weiteren Autor:innen. Beteiligte Einrichtung: Internal Medicine, Pfizer Research and Development, Groton, Connecticut, USA. Hauptthemen laut MEDLINE: Product Surveillance, Postmarketing, Drug-Related Side Effects and Adverse Reactions. Die Arbeit nennt 12 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Pfizer.
Abstract (Originalsprache)
Purpose
The objective of this analysis was to determine the contribution to the understanding of product benefit/risk made by non‐randomized, observational post‐marketing surveillance (PMS) studies previously required by the Ministry of Food and Drug Safety (MFDS) re‐examination system and conducted by Pfizer in Korea over 2000–2024.
Methods
A retrospective analysis of all Pfizer Korea PMS studies during 2000–2024 was performed, covering a wide range of therapy areas. Available Pfizer clinical study reports and re‐examination reports were reviewed for sample sizes, study periods, and key safety and effectiveness findings.
Results
Twenty‐four studies that enrolled 21 179 Korean participants were identified. Original sample sizes assigned by MFDS were typically either 600 or 3000 participants, but enrollment challenges were common and approximately half of the PMS studies were permitted to reduce sample size. Mean study duration (FSFV–LSLV) was 3.8 years. Safety findings were consistent with existing global safety data, with no clinically significant new safety information being generated from the PMS studies.
Conclusions
PMS conducted by Pfizer in Korea were often challenging to recruit and generated data that were consistent with prior global data, with no evidence of clinically meaningful differences in Korean patients. These findings support MFDS's recent transition to a risk management plan (RMP) framework, with PMS only as needed, reducing mandatory requirements for newly approved drug products. Furthermore, when a PMS study is necessary to address a specific scientific uncertainty, MFDS allows individual determination of the sample size, which will improve the feasibility of conducting the study.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Internal Medicine, Pfizer Research and Development, Groton, Connecticut, USA.
- Real World Evidence Generation, Pfizer Research and Development, Seoul, Korea.
- Portfolio Management, Pfizer Research and Development, New York, New York, USA.
- Internal Medicine, Pfizer Research and Development, Surrey, UK.
Förderung
- Pfizer
Zitieren
APA
Wolter, K., Jeong, S. H., Woo, J. W., Kim, E., Lee, Y., Cha, S., Moy, E., & Junor, R. (2026). Analysis of Mandatory Post‐Marketing Surveillance Studies Supports Revised Regulatory Requirements in Korea. Pharmacoepidemiology and Drug Safety, 35(5). https://doi.org/10.1002/pds.70382
Vancouver
Wolter K, Jeong SH, Woo JW, Kim E, Lee Y, Cha S, et al. Analysis of Mandatory Post‐Marketing Surveillance Studies Supports Revised Regulatory Requirements in Korea. Pharmacoepidemiology and Drug Safety. 2026;35(5). doi:10.1002/pds.70382
BibTeX
@article{Wolter2026,
author = {Wolter, Kevin and Jeong, Seung-Hee and Woo, Ju-Won and Kim, Eunsol and Lee, Yoosun and Cha, Sera and Moy, Evelyn and Junor, Rod},
title = {Analysis of Mandatory Post‐Marketing Surveillance Studies Supports Revised Regulatory Requirements in Korea},
journal = {Pharmacoepidemiology and Drug Safety},
year = {2026},
volume = {35},
number = {5},
doi = {10.1002/pds.70382}
}
EUVIMED